BNTX Живые сигналы | Максимизируйте прибыль с Getagraph.com

Купить 1684 min ago

@ €87.33

Выпущен: 26 апр. 2024 @ 19:27

Доходность: -0.14%

Предыдущий сигнал: апр. 25 - 20:47

Предыдущий сигнал: Продать

Доходность: 0.24 %

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	348 295
Средний объем	589 288
Рыночная капитализация	20.73B
EPS	€0 ( 2024-03-20 )
Дата следующего отчета о доходах	( €-0.410 ) 2024-05-06
Last Dividend	€2.11 ( 2022-06-02 )
Next Dividend	€0 ( N/A )
P/E	21.22
ATR14	€1.430 (1.64%)

Объем Корреляция

Длинно: -0.30 (neutral)

Кратко: -0.92 (very strong negative)

Signal:(35) Neutral

BioNTech SE Корреляция

10 Самые положительные корреляции
VERB	0.95
OPINL	0.946
BNGO	0.944
VRAY	0.944
AUDC	0.942
NESR	0.939
EGBN	0.939
CNXC	0.938
MAGS	0.938
AGIL	0.938

10 Самые отрицательные корреляции
XPDB	-0.94
ITAQ	-0.939
SWAV	-0.937
ROCL	-0.935
ATEC	-0.934
FTPA	-0.932
TIOA	-0.931
ROC	-0.931
CBRG	-0.93
BRIVU	-0.929

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

BioNTech SE Корреляция - Валюта/Сырье

-0.13
( neutral )

-0.18
( neutral )

0.00
( neutral )

0.08
( neutral )

0.16
( neutral )

-0.21
( neutral )

BioNTech SE Финансовые показатели

Annual	2023
Выручка:	€3.82B
Валовая прибыль:	€3.22B (84.29 %)
EPS:	€3.79

FY	2023
Выручка:	€3.82B
Валовая прибыль:	€3.22B (84.29 %)
EPS:	€3.79

FY	2022
Выручка:	€17.31B
Валовая прибыль:	€12.78B (73.82 %)
EPS:	€38.08

FY	2021
Выручка:	€18.98B
Валовая прибыль:	€15.12B (79.66 %)
EPS:	€40.63

Financial Reports:

No articles found.

BioNTech SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

BioNTech SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.73 - good (97.30%) | Divividend Growth Potential Score: 2.39 - No dividend growth expected in the near future

Information

First Dividend	€2.11	2022-06-02
Last Dividend	€2.11	2022-06-02
Next Dividend	€0	N/A
Payout Date	2022-06-17
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	€2.11	--
Avg. Dividend % Per Year	0.15%	--
Score	1.89	--
Div. Sustainability Score	9.73
Div.Growth Potential Score	2.39
Div. Directional Score	6.06	--

Next Divdend (Est)
(2024-04-27)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.89

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2022	€2.11	0.91%
2023	€0	0.00%
2024	€0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.244	1.500	5.13	7.69	[0 - 0.5]
returnOnAssetsTTM	0.0404	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0464	1.500	-0.596	-0.894	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.12	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.63	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00952	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	5.58	1.000	9.04	9.04	[3 - 30]
operatingCashFlowPerShareTTM	22.59	2.00	2.47	4.94	[0 - 30]
freeCashFlowPerShareTTM	19.63	2.00	0.186	0.373	[0 - 20]
debtEquityRatioTTM	0.0108	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.527	1.000	4.54	4.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.181	1.000	8.38	8.38	[0.1 - 0.6]
cashFlowToDebtRatioTTM	24.52	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.166	0.800	-2.23	-1.781	[0.5 - 2]
Total Score				9.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.83	1.000	8.00	0	[1 - 100]
returnOnEquityTTM	0.0464	2.50	-0.383	-0.894	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.63	2.00	3.46	0.373	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	22.59	2.00	2.47	4.94	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.406	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.39

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.